Eisai sales and marketing update

On Jan. 2, Eisai said it would launch Fycompa perampanel in the U.S. on Jan. 6 as adjunct treatment for partial onset seizures in patients with epilepsy

Read the full 273 word article

Trial Subscription

Get a two-week free trial subscription to BioCentury

SIGN UP

Article Purchase

This article may not be distributed to non-subscribers
More Info >PURCHASE